Search

Your search keyword '"Toffoletti, Eleonora"' showing total 3 results
Start Over Author "Toffoletti, Eleonora" Journal cancer medicine
3 results on '"Toffoletti, Eleonora"'

1. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”

Author

Di Giusto, Sara, primary, Toffoletti, Eleonora, additional, Bonifacio, Massimiliano, additional, Binotto, Gianni, additional, Miggiano, Maria Cristina, additional, Calistri, Elisabetta, additional, Stulle, Manuela, additional, Ermacora, Anna, additional, Stella, Rossella, additional, Scaffidi, Luigi, additional, D'Amore, Fabio, additional, Scotton, Giorgia, additional, Griguolo, Davide, additional, De Matteis, Giovanna, additional, Bertorelle, Roberta, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Fanin, Renato, additional, Damiani, Daniela, additional, and Tiribelli, Mario, additional

Published
2022
Full Text
View/download PDF

2. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC".

Author

Di Giusto, Sara, Toffoletti, Eleonora, Bonifacio, Massimiliano, Binotto, Gianni, Miggiano, Maria Cristina, Calistri, Elisabetta, Stulle, Manuela, Ermacora, Anna, Stella, Rossella, Scaffidi, Luigi, D'Amore, Fabio, Scotton, Giorgia, Griguolo, Davide, De Matteis, Giovanna, Bertorelle, Roberta, Krampera, Mauro, Semenzato, Gianpietro, Fanin, Renato, Damiani, Daniela, and Tiribelli, Mario

Subjects
*CHRONIC myeloid leukemia, *PROTEIN-tyrosine kinase inhibitors, *RECEIVER operating characteristic curves
Abstract

We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G‐TKIs) while in sustained deep molecular response. Patients were divided among those who maintained response (group 1, n = 123) and those who lost major molecular response (group 2, n = 45). Mean BCR::ABL1 RNA levels 1 month after discontinuation were higher in group 2 than in group 1 (p = 0.0005) and the difference was more evident 2 months after stop (p < 0.0001). The same trend was found both for imatinib and 2G‐TKIs. A receiver operating characteristic (ROC) analysis to determine a threshold value of BCR::ABL1 at 1 month after discontinuation identified a cut‐off value of 0.0051%, with 92.2% specificity, 31.7% sensitivity and a likelihood ratio of 4.087. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Author

Bernardi, Simona, primary, Malagola, Michele, additional, Zanaglio, Camilla, additional, Polverelli, Nicola, additional, Dereli Eke, Elif, additional, D’Adda, Mariella, additional, Farina, Mirko, additional, Bucelli, Cristina, additional, Scaffidi, Luigi, additional, Toffoletti, Eleonora, additional, Deambrogi, Clara, additional, Stagno, Fabio, additional, Bergamaschi, Micaela, additional, Franceschini, Luca, additional, Abruzzese, Elisabetta, additional, Divona, Maria Domenica, additional, Gobbi, Marco, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Cattaneo, Chiara, additional, Iurlo, Alessandra, additional, and Russo, Domenico, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results